Skip To Main Content
Ben Fidler on Muck Rack

Ben Fidler

Verified
Virginia
As seen in: BioPharma Dive, Industry Dive, Yahoo Finance, Yahoo, TechOhio, BioXconomy, NewsBreak, Food Dive, Healthcare Dive, Lexology, Supply Chain Dive, Yahoo Finanzas and
Biotech Journalist; Lead Editor, BioPharma Dive. Former Deputy Biotech Editor, Xconomy.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ben

Contact Ben, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

FDA scientists question Capricor data; Legend CEO steps down Original

|
By Ben Fidler Verified
| BioPharma Dive Verified
Today, a brief rundown of news involving Capricor Therapeutics and Legend Biotech, as well as updates from AstraZeneca, Outlook Therapeutics and Otsuka Pharmaceutical that you may have missed. Capricor Therapeutics shares lost nearly two-thirds of their value on Monday after briefing documents indicated that Food and Drug Administration staff reviewers are highly critical of the data supporting the company’s experimental cell therapy for Duchenne muscular dystrophy.
Open in Who Shared View Duplicates (3) Issue with article?

Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO Original

|
By Ben Fidler Verified
| BioPharma Dive Verified
Sarepta Therapeutics has found the leader it hopes can engineer a desperately needed turnaround. The company on Monday announced that Michael Severino, an executive with leadership experience at startups as well as large drugmakers, will become its next CEO effective July 28. He’ll replace longtime leader Doug Ingram, who in February announced plans to retire after a tumultuous run.
Open in Who Shared View Duplicates (2) Issue with article?

FDA panel endorses broader use of certain peptides Original

|
By Ben Fidler Verified
| BioPharma Dive Verified
Dive Brief: Advisers to the Food and Drug Administration have endorsed lifting restrictions that stop specialized compounding pharmacies from making certain peptides, heightening the chance that the agency could formally change its stance even as questions linger about their safety and effectiveness.
Open in Who Shared View Duplicates (2) Issue with article?
See all 3,491 articles